We hypothesize that if a synthetic UIM-containing peptide can be targeted to tumor vessels, it could competitively bind to the ubiquitylated VEGFR2 receptor and therefore block the epsin-VEGFR2 interaction, which could photocopy the knockout of epsins in tumor endothelial cells (TECs). Here, KDR is linked to neoplasm.